Primary Sclerosing Cholangitis versus Primary Biliary Cholangitis

Trace injury from the portal tract to the main duct

The same cholestatic labs can arise from very different levels of the biliary tree.

PBC begins in small portal-tract bile ducts, so routine cholangiography may remain normal despite progressive duct loss and biliary fibrosis.

PSC produces short annular strictures alternating with normal or mildly dilated segments, creating beading across the visible biliary tree.

A single distal blockage with smooth upstream dilation is a secondary obstruction pattern, not the multifocal map of PSC or the small-duct loss of PBC.

Build the diagnosis without an unnecessary ERCP

Cholestasis starts the workup, then noninvasive anatomy and targeted serology separate the branches.

Confirm a cholestatic pattern and use ultrasound to look for mechanical extrahepatic obstruction before labeling a primary cholangiopathy.

For suspected PSC, obtain high-quality MRI with MRCP; typical multifocal strictures with intervening normal or dilated segments usually make diagnostic ERCP and liver biopsy unnecessary.

For suspected PBC, a persistent alkaline phosphatase elevation plus antimitochondrial antibodies generally establishes the diagnosis after obstruction is excluded; biopsy is reserved for uncertainty, seronegative disease, or overlap concern.

Start with who and where

The demographic pattern helps, but the involved duct caliber is the decisive split.

PSC usually presents in younger or middle-aged adults, more often men, and commonly accompanies inflammatory bowel disease, especially ulcerative colitis.

PBC predominantly affects women in midlife and clusters with autoimmune thyroid disease, Sjogren syndrome, systemic sclerosis, and other autoimmune conditions.

PSC targets medium and large intrahepatic and extrahepatic ducts, whereas PBC primarily destroys small intrahepatic interlobular bile ducts.

Big ducts and bowel disease point to PSC; small ducts and systemic autoimmunity point to PBC.

Match the antibody and the scar

Serology carries PBC; cholangiography carries large-duct PSC.

AMA, usually directed against the pyruvate dehydrogenase complex, is highly characteristic of PBC, while atypical p-ANCA can occur in PSC but is neither required nor specific.

PBC biopsy shows nonsuppurative destructive cholangitis with a florid duct lesion and progressive ductopenia.

PSC may show concentric periductal onion-skin fibrosis, but the lesion is patchy and often missed, so a classic MRCP is more useful than routine biopsy.

Surveillance intensity follows the cancer map

PSC requires hepatobiliary and colorectal surveillance beyond routine cirrhosis care.

Adults with large-duct PSC should undergo annual surveillance for cholangiocarcinoma and gallbladder carcinoma, preferably with MRI/MRCP with or without CA 19-9; CA 19-9 is an adjunct, not a stand-alone diagnosis.

In PSC, gallbladder polyps at most 8 mm may be followed with ultrasound every 6 months, while polyps greater than 8 mm prompt consideration of cholecystectomy at an experienced center after liver risk is weighed.

PSC with IBD requires high-definition surveillance colonoscopy every 1 to 2 years. HCC surveillance is added when cirrhosis is present; PBC follows cirrhosis and other disease-specific HCC risk principles rather than PSC cholangiocarcinoma surveillance.

Do not prescribe PBC treatment to PSC by reflex

UDCA has different evidence and goals in these two diseases.

PBC should receive UDCA 13 to 15 mg/kg/day, with biochemical response assessed after about 12 months; inadequate response or intolerance warrants specialist reassessment using current second-line options and liver stage.

Obeticholic acid was withdrawn from the United States market in 2025, so an old PBC pathway that automatically adds it is no longer current.

PSC has no established medical cure. AASLD allows selected adults with persistently elevated ALP or GGT to try UDCA 13 to 23 mg/kg/day and continue only with meaningful biochemical or symptom improvement at 12 months; high-dose therapy is harmful.

Transplant evaluation is appropriate for decompensated liver disease, recurrent bacterial cholangitis, intractable pruritus, or selected early perihilar cholangiocarcinoma under specialized protocols.

UDCA is foundational in PBC and conditional in PSC.